Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × relugolix × Genitourinary × Clear all

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 29 Observational 1

Sponsor

Cancer Type

Gynecologic 1 Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Surveys and Questionnaires 42 Blood Specimen Collection 39 enzalutamide 25 radium Ra 223 dichloride 19 Biopsy 18 apalutamide 16 Docetaxel 16 Abiraterone Acetate 16 Watchful Waiting 15 Radiotherapy 15 Magnetic Resonance Spectroscopy 15 darolutamide 14 Sunitinib 13 Sorafenib 13 Leuprolide 13 Interviews as Topic 13 Gene Expression Profiling 13 Specimen Handling 11 Observation 11 Magnetic Resonance Imaging 11 Amplified Fragment Length Polymorphism Analysis 11 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 10 Androgen Antagonists 10 abiraterone 9 avelumab 8 Radiosurgery 8 Immunohistochemistry 8 Data Collection 8 Polymerase Chain Reaction 7 Hematologic Tests 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05467176 2025-08-17

OPTYX

Sumitomo Pharma America, Inc.

Active not recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡